8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

^{______________}

FORM 8-K

^{______________}

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 4, 2009

^{______________}

Stellar Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

^{______________}

Ontario, Canada	0-31198	Not Applicable
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

544 Egerton Street, London, Ontario, Canada, N5W 3Z8

(Address of Principal Executive Office) (Zip Code)

(519) 434-1540

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01

Regulation FD Disclosure

See Exhibit 99.1

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.	Description
99.1	Stellar Pharmaceuticals to Host Second Quarter 2009 Earnings Conference Call

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

STELLAR PHARMACEUTICALS INC.
By:	/s/ PETER RIEHL
	Peter Riehl President and Chief Executive Officer

Date:  August 4, 2009

EX-99.1

Exhibit 99.1

STELLAR PHARMACEUTICALS TO HOST SECOND QUARTER 2009 EARNINGS CONFERENCE CALL

·

Company to hold Conference Call Wednesday, August 5 at 11:00 am ET

·

Stellar has three consecutive quarters showing profit

·

Q2 2009 revenues increase 65.8% to $1.1 million

LONDON, Ontario – August 4, 2009 -  Stellar Pharmaceuticals Inc., (OCTBB:SLXCF) ("Stellar" or "the Company"), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced today that the Company intends to release its second quarter 2009 financial results on Wednesday, August 5, 2009 prior to the open of the U.S. financial markets. The Company will also host a conference call at 11:00 a.m. Eastern Daylight Time on August 5, 2009 to discuss its financial results and provide an update on the Company's outlook for 2009.

The dial-in number to access the call is (416) 340-8018, or toll free North America (866) 223-7781.  A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Daylight Time on August 19, 2009. The replay may be accessed by dialing (800) 408-3053 and entering pass code 8486086.                        

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology:  NeoVisc®, for the treatment of osteoarthritis; and Uracyst®, its patented technology for treatment of interstitial cystitis/painful bladder syndrome an inflammatory disease of the urinary bladder wall.  Stellar also has in-licensing agreement for the distribution and sale of NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

For More Information Please Contact:

Stellar Pharmaceuticals Inc.  

Arnold Tenney

Peter Riehl

or

(416) 587-3200

President & CEO

(800) 639-0643 or (519) 434-1540

email: Corpinfo@StellarPharma.com